Market Outperform Rating Reiterated for Allakos Amid Promising AK006 Clinical Developments

20h ago, source:

Analyst Jonathan Wolleben from JMP Securities reiterated a Buy rating on Allakos (ALLK – Research Report) and keeping the price target at ...

Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

1mon ago, source: Business Insider

SAN CARLOS, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory ...

Allakos Inc 37Z

14d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

1mon ago, source: Stockhouse

SAN CARLOS, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, ...

Allakos (ALLK): Strong Industry, Solid Earnings Estimate Revisions

20d ago, source: Zacks.com on MSN

Allakos (ALLK) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Allakos Inc. (37Z.F)

1mon ago, source: Yahoo Finance

Feb. 26, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics that target immunomodulatory receptors present on immune effector cells ...

Allakos Inc.: Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

1mon ago, source: Finanznachrichten

ALLAKOS INC. UNAUDITED CONDENSED BALANCE SHEETS (in thousands) December 31, 2023 2022 Assets Current assets: Cash and cash equivalents $ 66,440 $ 87,217 Investments 104,354 192,569 Prepaid ...